{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:51:12Z","timestamp":1792144272384,"version":"4.4.0"},"reference-count":49,"publisher":"Elsevier","isbn-type":[{"value":"9780128167588","type":"print"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1016\/bs.apha.2019.02.003","type":"book-chapter","created":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T20:39:07Z","timestamp":1552595947000},"page":"187-205","source":"Crossref","is-referenced-by-count":21,"title":["Non-dopaminergic vs. dopaminergic treatment options in restless legs syndrome"],"prefix":"10.1016","member":"78","reference":[{"issue":"11","key":"10.1016\/bs.apha.2019.02.003_bb0010","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/archneur.1982.00510230065027","article-title":"Treatment of restless legs syndrome with levodopa plus benserazide","volume":"39","author":"Akpinar","year":"1982","journal-title":"Archives of Neurology"},{"issue":"7","key":"10.1016\/bs.apha.2019.02.003_bb0015","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1303646","article-title":"Comparison of pregabalin with pramipexole for restless legs syndrome","volume":"370","author":"Allen","year":"2014","journal-title":"The New England Journal of Medicine"},{"issue":"3","key":"10.1016\/bs.apha.2019.02.003_bb0020","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/sleep\/19.3.205","article-title":"Augmentation of the restless legs syndrome with carbidopa\/levodopa","volume":"19","author":"Allen","year":"1996","journal-title":"Sleep"},{"issue":"5","key":"10.1016\/bs.apha.2019.02.003_bb0025","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.sleep.2011.03.003","article-title":"Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample","volume":"12","author":"Allen","year":"2011","journal-title":"Sleep Medicine"},{"issue":"2","key":"10.1016\/bs.apha.2019.02.003_bb0030","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1389-9457(03)00010-8","article-title":"Restless legs syndrome: Diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health","volume":"4","author":"Allen","year":"2003","journal-title":"Sleep Medicine"},{"issue":"15","key":"10.1016\/bs.apha.2019.02.003_bb0035","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1002\/mds.23326","article-title":"Decision making in restless legs syndrome","volume":"25","author":"Bayard","year":"2010","journal-title":"Movement Disorders"},{"issue":"1","key":"10.1016\/bs.apha.2019.02.003_bb0040","first-page":"81","article-title":"Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: A case-control study","volume":"33","author":"Cornelius","year":"2010","journal-title":"Sleep"},{"issue":"2","key":"10.1016\/bs.apha.2019.02.003_bb0045","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/WNF.0b013e31820d6699","article-title":"The emergence of devastating impulse control disorders during dopamine agonist therapy of the restless legs syndrome","volume":"34","author":"Dang","year":"2011","journal-title":"Clinical Neuropharmacology"},{"issue":"5","key":"10.1016\/bs.apha.2019.02.003_bb0050","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/wnf.0b013e31804c780e","article-title":"Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome","volume":"30","author":"Driver-Dunckley","year":"2007","journal-title":"Clinical Neuropharmacology"},{"issue":"4","key":"10.1016\/bs.apha.2019.02.003_bb0055","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/mds.21303","article-title":"Dopamine agonist-induced pathological gambling in restless legs syndrome due to multiple sclerosis","volume":"22","author":"Evans","year":"2007","journal-title":"Movement Disorders"},{"issue":"Suppl","key":"10.1016\/bs.apha.2019.02.003_bb0060","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/S1389-9457(02)00144-2","article-title":"Restless legs syndrome augmentation and pramipexole treatment","volume":"3","author":"Ferini-Strambi","year":"2002","journal-title":"Sleep Medicine"},{"key":"10.1016\/bs.apha.2019.02.003_bb0065","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.sleep.2016.08.019","article-title":"In search of alternatives to dopaminergic ligands for the treatment of restless legs syndrome: Iron, glutamate, and adenosine","volume":"31","author":"Ferre","year":"2017","journal-title":"Sleep Medicine"},{"key":"10.1016\/bs.apha.2019.02.003_bb0070","article-title":"New insights into the neurobiology of restless legs syndrome","author":"Ferre","year":"2018","journal-title":"The Neuroscientist"},{"issue":"5","key":"10.1016\/bs.apha.2019.02.003_bb0075","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.sleep.2007.03.022","article-title":"Diagnostic standards for dopaminergic augmentation of restless legs syndrome: Report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute","volume":"8","author":"Garcia-Borreguero","year":"2007","journal-title":"Sleep Medicine"},{"key":"10.1016\/bs.apha.2019.02.003_bb0080","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.sleep.2017.03.012","article-title":"Treatment of restless legs syndrome with the selective AMPA receptor antagonist perampanel","volume":"34","author":"Garcia-Borreguero","year":"2017","journal-title":"Sleep Medicine"},{"key":"10.1016\/bs.apha.2019.02.003_bb0085","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.sleep.2018.11.025","article-title":"Reduced response to gabapentin enacarbil in restless legs syndrome following long-term dopaminergic treatment","volume":"55","author":"Garcia-Borreguero","year":"2018","journal-title":"Sleep Medicine"},{"key":"10.1016\/bs.apha.2019.02.003_bb0090","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.sleep.2018.02.002","article-title":"Treatment of restless legs syndrome\/Willis-Ekbom disease with the non-selective ENT1\/ENT2 inhibitor dipyridamole: Testing the adenosine hypothesis","volume":"45","author":"Garcia-Borreguero","year":"2018","journal-title":"Sleep Medicine"},{"issue":"2","key":"10.1016\/bs.apha.2019.02.003_bb0095","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/mds.24889","article-title":"Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom disease): Results from a prospective, multicenter study over 66 weeks","volume":"27","author":"Garcia-Borreguero","year":"2012","journal-title":"Movement Disorders"},{"issue":"5","key":"10.1016\/bs.apha.2019.02.003_bb0100","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.sleep.2007.03.023","article-title":"Validation of the augmentation severity rating scale (ASRS): A multicentric, prospective study with levodopa on restless legs syndrome","volume":"8","author":"Garcia-Borreguero","year":"2007","journal-title":"Sleep Medicine"},{"issue":"7","key":"10.1016\/bs.apha.2019.02.003_bb0105","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.sleep.2013.05.016","article-title":"The long-term treatment of restless legs syndrome\/Willis-Ekbom disease: Evidence-based guidelines and clinical consensus best practice guidance: A report from the international restless legs syndrome study group","volume":"14","author":"Garcia-Borreguero","year":"2013","journal-title":"Sleep Medicine"},{"issue":"23","key":"10.1016\/bs.apha.2019.02.003_bb0110","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1212\/WNL.0b013e3181e1ce73","article-title":"Treatment of restless legs syndrome with pregabalin: A double-blind, placebo-controlled study","volume":"74","author":"Garcia-Borreguero","year":"2010","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/bs.apha.2019.02.003_bb0115","doi-asserted-by":"crossref","first-page":"635","DOI":"10.5665\/sleep.3558","article-title":"Pregabalin versus Pramipexole: Effects on sleep disturbance in restless legs syndrome","volume":"37","author":"Garcia-Borreguero","year":"2014","journal-title":"Sleep"},{"key":"10.1016\/bs.apha.2019.02.003_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.sleep.2016.01.017","article-title":"Guidelines for the first-line treatment of restless legs syndrome\/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: A combined task force of the IRLSSG, EURLSSG, and the RLS-foundation","volume":"21","author":"Garcia-Borreguero","year":"2016","journal-title":"Sleep Medicine"},{"issue":"5","key":"10.1016\/bs.apha.2019.02.003_bb0125","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.smrv.2009.11.006","article-title":"Dopaminergic augmentation of restless legs syndrome","volume":"14","author":"Garcia-Borreguero","year":"2010","journal-title":"Sleep Medicine Reviews"},{"issue":"4","key":"10.1016\/bs.apha.2019.02.003_bb0130","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/WCO.0000000000000117","article-title":"An update on restless legs syndrome (Willis-Ekbom disease): Clinical features, pathogenesis and treatment","volume":"27","author":"Garcia-Borreguero","year":"2014","journal-title":"Current Opinion in Neurology"},{"issue":"2","key":"10.1016\/bs.apha.2019.02.003_bb0135","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1212\/WNL.43.2.445","article-title":"Dopaminergic treatment of restless legs and rebound phenomenon","volume":"43","author":"Guilleminault","year":"1993","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/bs.apha.2019.02.003_bb0140","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.sleep.2010.12.007","article-title":"Efficacy and augmentation during 6 months of double-blind pramipexole for restless legs syndrome","volume":"12","author":"H\u00f6gl","year":"2011","journal-title":"Sleep Medicine"},{"issue":"2","key":"10.1016\/bs.apha.2019.02.003_bb0145","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.smrv.2013.03.004","article-title":"What treatment works best for restless legs syndrome? Meta-analyses of dopaminergic and non-dopaminergic medications","volume":"18","author":"Hornyak","year":"2014","journal-title":"Sleep Medicine Reviews"},{"issue":"3","key":"10.1016\/bs.apha.2019.02.003_bb0150","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.sleep.2011.09.013","article-title":"Efficacy and safety of dopamine agonists in restless legs syndrome","volume":"13","author":"Hornyak","year":"2012","journal-title":"Sleep Medicine"},{"issue":"3","key":"10.1016\/bs.apha.2019.02.003_bb0155","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0033-3182(10)70695-2","article-title":"Impact of dopamine agonists on compulsive behaviors: A case series of pramipexole-induced pathological gambling","volume":"51","author":"Kolla","year":"2010","journal-title":"Psychosomatics"},{"issue":"10","key":"10.1016\/bs.apha.2019.02.003_bb0160","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.sleep.2012.08.004","article-title":"Long-term use of pramipexole in the management of restless legs syndrome","volume":"13","author":"Lipford","year":"2012","journal-title":"Sleep Medicine"},{"issue":"10","key":"10.1016\/bs.apha.2019.02.003_bb0165","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.sleep.2015.05.028","article-title":"Natural course of restless legs syndrome\/Willis-Ekbom disease: Long-term observation of a large clinical cohort","volume":"16","author":"Mitterling","year":"2015","journal-title":"Sleep Medicine"},{"issue":"1","key":"10.1016\/bs.apha.2019.02.003_bb0170","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.parkreldis.2007.05.006","article-title":"Predictors of impulsivity and reward seeking behavior with dopamine agonists","volume":"14","author":"Ondo","year":"2008","journal-title":"Parkinsonism & Related Disorders"},{"issue":"9","key":"10.1016\/bs.apha.2019.02.003_bb0175","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1001\/archneur.61.9.1393","article-title":"Long-term treatment of restless legs syndrome with dopamine agonists","volume":"61","author":"Ondo","year":"2004","journal-title":"Archives of Neurology"},{"issue":"1\u20132","key":"10.1016\/bs.apha.2019.02.003_bb0180","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jns.2009.11.010","article-title":"Compulsive habits in restless legs syndrome patients under dopaminergic treatment","volume":"290","author":"Pourcher","year":"2010","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1016\/bs.apha.2019.02.003_bb0185","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.parkreldis.2006.10.001","article-title":"Pathological gambling associated with dopamine agonist use in restless legs syndrome","volume":"13","author":"Quickfall","year":"2007","journal-title":"Parkinsonism & Related Disorders"},{"key":"10.1016\/bs.apha.2019.02.003_bb0190","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.neuropharm.2016.09.002","article-title":"Adenosine receptors as markers of brain iron deficiency: Implications for restless legs syndrome","volume":"111","author":"Quiroz","year":"2016","journal-title":"Neuropharmacology"},{"issue":"5","key":"10.1016\/bs.apha.2019.02.003_bb0195","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/sleep\/32.5.587","article-title":"A case of compulsive behaviors observed in a restless legs syndrome patient treated with a dopamine agonist","volume":"32","author":"Salas","year":"2009","journal-title":"Sleep"},{"issue":"2","key":"10.1016\/bs.apha.2019.02.003_bb0200","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.parkreldis.2011.10.010","article-title":"Transdermal rotigotine causes impulse control disorders in patients with restless legs syndrome","volume":"18","author":"Schreglmann","year":"2012","journal-title":"Parkinsonism & Related Disorders"},{"issue":"7","key":"10.1016\/bs.apha.2019.02.003_bb0205","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/sleep\/26.7.819","article-title":"Pramipexole in the management of restless legs syndrome: An extended study","volume":"26","author":"Silber","year":"2003","journal-title":"Sleep"},{"issue":"10","key":"10.1016\/bs.apha.2019.02.003_bb0210","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1093\/sleep\/20.10.878","article-title":"Pergolide in the management of restless legs syndrome: An extended study","volume":"20","author":"Silber","year":"1997","journal-title":"Sleep"},{"issue":"5","key":"10.1016\/bs.apha.2019.02.003_bb0215","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.sleep.2010.11.002","article-title":"A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome","volume":"12","author":"Silver","year":"2011","journal-title":"Sleep Medicine"},{"issue":"4","key":"10.1016\/bs.apha.2019.02.003_bb0220","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1212\/01.wnl.0000252368.25106.b6","article-title":"Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists","volume":"68","author":"Tippmann-Peikert","year":"2007","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/bs.apha.2019.02.003_bb0225","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S1474-4422(15)00243-4","article-title":"Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson's disease (PANDA): A double-blind, randomised, placebo-controlled trial","volume":"14","author":"Trenkwalder","year":"2015","journal-title":"Lancet Neurology"},{"key":"10.1016\/bs.apha.2019.02.003_bb0230","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2377-11-117","article-title":"Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome","volume":"11","author":"Voon","year":"2011","journal-title":"BMC Neurology"},{"key":"10.1016\/bs.apha.2019.02.003_bb0235","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1212\/WNL.0000000000003388","article-title":"Practice guideline summary: Treatment of restless legs syndrome in adults: Report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology","volume":"87","author":"Winkelman","year":"2016","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/bs.apha.2019.02.003_bb0240","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.sleep.2003.07.005","article-title":"Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS)","volume":"5","author":"Winkelman","year":"2004","journal-title":"Sleep Medicine"},{"key":"10.1016\/bs.apha.2019.02.003_bb0245","doi-asserted-by":"crossref","DOI":"10.1002\/mds.27260","article-title":"Treatment of restless legs syndrome: An evidence-based review and implications for clinical practice","author":"Winkelmann","year":"2018","journal-title":"Movement Disorders"},{"issue":"6","key":"10.1016\/bs.apha.2019.02.003_bb0250","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/ana.25104","article-title":"Targeting hypersensitive corticostriatal terminals in restless legs syndrome","volume":"82","author":"Yepes","year":"2017","journal-title":"Annals of Neurology"}],"container-title":["Advances in Pharmacology","Pharmacology of Restless Legs Syndrome (RLS)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1054358919300110?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1054358919300110?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T11:44:18Z","timestamp":1760960658000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1054358919300110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9780128167588"],"references-count":49,"URL":"https:\/\/doi.org\/10.1016\/bs.apha.2019.02.003","relation":{},"ISSN":["1054-3589"],"issn-type":[{"value":"1054-3589","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}